Hetrombopag has demonstrated strong efficacy and a favourable safety profile in children with immune thrombocytopenia, according to newly published clinical findings. The data support the use of the thrombopoietin receptor agonist as an effective second-line treatment option in paediatric patients who do not respond adequately to first-line therapy. Immune thrombocytopenia…
RamRajya News
Heralding RamRajya in Bharat